Fitzsimons Innovation Community is an integrated urban campus where health and life sciences companies of all sizes work on their next big things. Our customized workspace, collaborative campus, and proximity to one of the top health systems and medical schools in the country make our community the perfect place to put down roots and get to work.
MOVE-IN READY LAB SPACE
GROWTH OPPORTUNITIES
It’s not just additional space—it’s fifty sprawling acres of additional space. And it’s primed for ultra-custom, made-to-order facility development.
Fitzsimons Innovation Community and University of Colorado Anschutz Medical Campus working together.
Relationships that help you thrive.
FEATURED:
One of the most exciting times of year for us here at Fitzsimons Innovation Community is when we launch our Annual Innovation Report, and this year is no different. For the fourth year in a row, we are proud to share this report featuring updates, insight, and data about all the things that make our Community special.
Fitzsimons Innovation Community is where innovators come to turn ideas into business.
A regular feature of a Fitzsimons Innovation Community visionary.
Our year in innovation.
Find out what’s happening on campus and across the industry.
An urban mountain lifestyle for work and play.
Everything you need.
Right here.
Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.
Fitzsimons Innovation Community President & CEO Kelly Brough was recently featured on Visit Aurora, Colorado's The Gateway to the Rockies Podcast where she shared the bold vision behind the newly approved master plan and how the Fitzsimons campus is transforming into Aurora’s first true urban district. From cutting-edge research that's reshaping patient care to green spaces, housing innovation, public art, and world-class labs, she dives into how Fitzsimons is redefining what it means to live, work, and discover in Colorado.
CU Anschutz researchers help lead the largest U.S. randomized trial highlighting ketamine’s cardiovascular risks while guiding emergency and critical care practice.
As we close out this milestone year celebrating our 25th anniversary, we've been reflecting on the incredible journey from visionary concept to thriving hub of health and life sciences innovation. Throughout 2025, we've shared fun insights on social media about the lessons learned, the a-ha moments discovered, and the collective wisdom gathered from the brilliant minds who call our Community home. Now, we're bringing all the fun together in one place—a celebration of what makes Fitzsimons Innovation Community truly special.
A new multi-site study led by researchers at CU Anschutz shows that people with cystic fibrosis (CF) who start the triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many of their daily lung treatments while maintaining good health for years.
A first-of-its-kind combination therapy could make treatment more effective by attacking hard-to-treat cancer from two angles.
Fitzsimons Innovation Community
